Company profile
OPUS GENETICS, INC.
NASDAQ:IRDBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| ERENAPURSTAT | phase2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (17)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT06542497 | phase3 | completed | 2024-08-15 | 2025-04-03 | Opus Genetics, Inc | Evaluate Efficacy and Safety of POS to Improve Distance-corrected Near Visual in Participants With Presbyopia |
| NCT05223478 | phase3 | completed | 2021-12-17 | 2022-04-18 | Opus Genetics, Inc | Nyxol (0.75% Phentolamine Ophthalmic Solution) to Reverse Pharmacologically-Induced Mydriasis in Pediatric Subjects |
| NCT07140783 | phase3 | recruiting | 2025-09-02 | 2027-08-01 | Opus Genetics, Inc | OPI-NXYDLD-303 Safety and Efficacy of Phentolamine Ophthalmic Solution in Keratorefractive Surgery Participants With Decreased Mesopic Visual Acuity |
| NCT06349759 | phase3 | completed | 2024-04-01 | 2025-04-17 | Opus Genetics, Inc | Safety and Efficacy of 0.75% Phentolamine Ophthalmic Solution in Subjects With Post-refractive Surgery Visual Disturbances |
| NCT04638660 | phase3 | completed | 2020-12-30 | 2022-05-19 | Opus Genetics, Inc | Safety and Efficacy of Nyxol (0.75% Phentolamine Ophthalmic Solution) in Subjects With Dim Light Vision Disturbances |
FDA applications (0)
No records yet.